Banner
Home
Search by IDs Search by Gene
Browse
Patient Tumour & Clinical details PDX & PDXBiomarker details
Update
With gene expression Without gene expression Mutation & CNV Plot
Summary



PDX model details

PDX ID 382M
Host Strain(and Source) NSG
Source: Monash University
Host Strain Immune system Humanized NO
Host Type Testosterone supplemented
Graft Site Renal
Current Generation
(* indicates number of generations grown in Castrate host)
 11
Average PDX Generation Time (days +/- SEM) 41 ± 4
Tumour preparation Tumor solid
Tumour Characterization Technology Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq
Tumour confirmed not to be of Mouse/EBV origin Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC
Passage QA performed Routine QA every 2-3 passages
Associated meta data
PDX model availability Yes (fixed, frozen)
Governance restriction for distribution Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements
Pubmed ID 34413304
Markers 382M
AR Y
PSA Y
PSMA Y
NE N
ERG N
This heatmap displays the call type of curated CNVs in the presented samples.
This heatmap displays the call type of CNVs in commonly occurred samples.

PDX ID Gene Symbol CNV Log2 CNV Copy CNV Call Experiments name Platform Reference genome
382M CHD1 -14.854 6.760e-05 Homdel MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
382M AR -5.064 0.030 GSR MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
382M FANCA -1.427 0.744 Loss MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
382M TP53 -1.403 0.757 Loss MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
382M PTEN -0.967 1.023 Loss MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
382M SUFU -0.967 1.023 Loss MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
382M KMT2C -0.949 1.036 Loss MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
382M RB1 -0.923 1.055 Loss MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
382M CDKN1B -0.861 1.101 Loss MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
382M KMT2C 0.538 2.903 Gain MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
382M PIK3CA 0.596 3.023 Gain MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
382M CTNNB1 0.644 3.125 Gain MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
382M PIK3CB 0.971 3.921 Gain MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19
382M MYC 1.164 4.482 Gain MURAL Prostate Cancer PDX collection Targeted GARVAN Panel hg19

Clinical Information

Sample Number 382M
Sample Site Liver
Sample source Biopsy
Pathology Tumour Diagnosis None
Gleason Score None
Primary Gleason Score None
Secondary Gleason Score None
Tertiary Gleason Score None
ISUP Grade Group
Tumour Grade
D'Amico Risk Classification
Tumour Volume (in cc) 0.0
Treatment Prior to Specimen Collection ADT, docetaxel, cabazitaxel, abiraterone

Patient Information

Patient Number 175/382
Sex Male
Diagnosis Prostate Cancer
PSA at diagnosis (ng/mL) NA
Consent to share data

Patient Tumour Collection (Current Model)
Tumour sample ID 382M
Patient Age (binned in 5 year age groups) 70-74
This heatmap displays the mutations of curated sequence variants.
Download Plot
The Mut plot is not shown
PDX ID Gene Symbol Total Read Depth Alternate Frequency Consequence Exon GnomAD AF CADD PHRED score ClinVar significance Platform Experiments Name Reference Library Type Instrument Type
382M BTK 181 0.99 Missense variant '12/19 . 26.9 - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
382M PTEN 227 0.98 Missense variant '5/9 . 27.2 - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
382M PTCH1 393 0.51 Missense variant '9/24 0.0007269 23.6 Conflicting interpretations of pathogenicity Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
382M SETD2 404 0.48 Missense variant '3/21 0.0005031 29.4 - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
382M LRP2 351 0.47 Missense variant '22/79 . 0.437 - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
382M SPOP 370 0.46 Missense variant '7/12 4.07E-06 23.7 Conflicting interpretations of pathogenicity Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
382M GRIN2A 1018 0.35 Missense variant '13/14 . 24.9 Uncertain significance Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
382M EPHA5 359 0.32 Frameshift variant '1/18 . . - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
382M MYCN 234 0.31 Inframe deletion '2/3 . . - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500
382M AR 381 0.27 GSR '1/8 . . - Targeted GARVAN Panel MURAL Prostate Cancer PDX collection hg19 paired Illumina HiSeq 2500